About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Nucleic Acid Therapeutics

formerly Oligonucleotides

Co-Editors-in-Chief: Bruce A. Sullenger, PhD and C.A. Stein, MD, PhD

ISSN: 2159-3337 • Published Bimonthly • Online ISSN: 2159-3345

Current Volume: 24

Latest Impact Factor* is 2.914

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    The leading peer-reviewed journal in its field, focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids.  Comprehensive coverage includes oligonucleotides; RNAi: siRNAs, shRNAs, and miRNAs; aptamers; RNA nanoparticles; gene modification with oligos; antisense applications; nucleoside and nucleotide analogs; peptide nucleic acids; ribozymes; and DNA-modified gene therapy.

    Manuscripts must be submitted online using the following URL: http://mc.manuscriptcentral.com/nucleicacidtherapeut 

    PLEASE READ ALL THE INSTUCTIONS TO AUTHORS BEFORE SUBMITTING.

     

    Preparation of Manuscript. Manuscripts should be submitted double-spaced.  Leave ample margins on both sides, top and bottom.

    Be prepared to give the title of the article, name(s) of the author(s) and institutional affiliation(s), and supply a running title of about 45 characters. You also will be required to supply an abstract of about 200 words, stating the aims, results, and conclusions drawn from the study. This should be followed by the Introduction, Materials and Methods, Results, Discussion, Acknowledgments, references, tables, figures, and figure legends. Begin each of these sections on a separate page. We require an e-mail address for each author listed on your article. Authors should review the style and clarity of their manuscripts with colleagues before submission, especially if English is not their native language, to ensure clear grammatical English usage. The editors welcome suggestions concerning potential reviewers. We encourage authors to report all of the oligonucleotides or constructs that were studied, not just those that gave the “best” result. Authors should also note the editorial policy of this journal, as described in C.A. Stein and A. Krieg, “Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides,” Antisense and Nucleic Acid Drug Development, 1994, (4), 67–69. All manuscripts that claim antisense efficacy must, in addition to the antisense oligodeoxynucleotide construct, include at least two control oligodeoxynucleotides. The sequences of the two controls are to be decided by the authors. Manuscripts that do not include at least two controls will be returned without review.

    Brief Communications may be submitted to report negative findings, useful techniques, or unusual artifacts, or to present studies that are interesting but not definitive enough to warrant publication as a full-length manuscript. In a Brief Communication, the Results and Discussion sections may be combined, the Abstract should be limited to about 150 words, and there should be no more than three figures or tables.

    All authors of a manuscript must have agreed to its submission and are equally responsible for its content. By submitting a manuscript, the authors guarantee that the manuscript, or one substantially the same, was not published previously and is not being considered or published elsewhere. A preliminary disclosure of research findings published in abstract form as an adjunct to a meeting is not considered prior publication.

    Copies of “in press” and “submitted” manuscripts that are important for consideration of the present manuscript should be enclosed to facilitate the review process. Include written permission to cite any personal communications and preprints.

    Every effort will be made to complete the review process within 4–6 weeks of receipt of the manuscript.

    Tables and Illustrations. Use arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences.

    Bar graphs should use different fill patterns (e.g., horizontal or diagonal lines) rather than variations in gray scale shading, which do not print well.

    Please observe the following guidelines when submitting art:

    Do not include any illustrations as part of your text file.
    Do not prepare any figures in Word as they are not workable.
    • Line illustrations must be submitted at 1200 DPI.
    • Halftones and color photos should be submitted at a minimum of 300 DPI.
    • Adobe is the preferred software. Avoid submitting PowerPoint files.
    • Save art as either TIFF or EPS files. Avoid submitting JPEG files.
    • Color art must be saved as CYMK, not RGB.

    The Journal will publish color photographs, but the author must subsidize the cost of the color printing. For further details, contact the Publisher.

    Disclosure Statement
     
    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.htlm#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."


    When naming your figure files, please label them with your manuscript number, followed by a period (.), and then list the figure number.  Ex:  MET-2008-0123.Fig1.  Label figures and tables inside the files in addition to naming the file with the figure or table number.  (ie:  When figures or table files are opened, the figure or table number should appear inside the file.)

    IMPORTANT:

    Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper.  Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.

    If no conflicts exist, the authors must state “No competing financial interests exist."

    References may be made to published work and papers in press. Reference citations are not permitted in the abstract of a paper.  Authors are responsible for the accuracy of all literature citations.  Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text.  References should be listed numerically in the text in the order of appearance as parenthesized consecutive numbers, e.g., [1,2]. Where there are more than two references, the citation should appear as hyphenated numbers, e.g., [1–3]. References should be typed double-spaced in numerical order of citation, with all authors listed.  Abbreviations of journals should conform to those used in Medline. The following formats must be used:

    Journal article(s):

    Sugita H and S Takeda. (2010). Progress in muscular dystrophy research with special emphasis on gene therapy. Proc Jpn Acad Ser 86:748–756.

    Malerba A, L Boldrin and G Dickson. (2011). Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther 21:293–298.

    Aartsma-Rus A, I Fokkema, JJ Verschuuren, HB Ginjaar, JCT van Deutekom, GJB van Ommen and JT den Dunnen. (2009). Applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293–299.

    Book:
    Gerwitz AM, ed.  Nucleic Acid Therapeutics in Cancer (Cancer Drug Discovery and Development). (2004).  Humana Press, New York, NY.

    Chapter in a Book:
    Rogers FA, Glazer PM. Targeted genome modification via triple helix formation.  In:  Nucleic Acid Therapeutics in Cancer (Cancer Drug Discovery and Development).  Gerwitz AM, ed.   (2004).  Humana Press, New York, NY; pp.  27-44.

    Website:  (Provide these elements, with the following punctuation):
    Authors [last name, first/middle initials; if available].   Title of article on website.  Website address. Last accessed date.

    Permissions. The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote of a reprinted table, or of the legend of a reprinted figure, should read, “reprinted by permission from Doe et al.” and list the appropriate reference. All permission listings must be shown in the manuscript; they cannot be entered on proofs.
     
    Reprints.

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    Nucleic Acid Therapeutics is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101.

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Human Gene Therapy

    Human Gene Therapy

    The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

    Genetic Testing and Molecular Biomarkers

    Genetic Testing and Molecular Biomarkers

    Covers all areas of molecular, biochemical, and clinical genetic testing; ethical, legal, social, and economic aspects of genetic testing; issues concerning effective genetic counseling; and molecular biomarkers.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

Browse All Publications »